Humana has agreed to sell all or substantially all of its remaining minority stake in Gentiva for approximately $900 million. The transaction marks the final step in the health insurer’s multi-year plan to exit the hospice and palliative care business. The sale also reflects Humana’s renewed focus on its core healthcare and Medicare Advantage operations.
The agreement is expected to close during the third quarter of 2026, pending regulatory approvals and customary closing conditions. Company leaders indicated that the proceeds will support general corporate purposes and are not expected to materially affect Humana’s 2026 earnings.
Why Humana Is Selling Its Remaining Gentiva Stake
Humana has steadily streamlined its business portfolio over the last several years. The company originally acquired its ownership position through the purchase of the remaining interest in Kindred at Home in 2021. At that time, Humana announced plans to eventually divest non-core assets, including hospice, palliative care, and personal healthcare operations.
As healthcare organizations continue to focus on operational efficiency, many insurers are concentrating resources on businesses that directly support their long-term growth objectives. Consequently, Humana decided to complete its separation from the end-of-life care sector.
Furthermore, the move allows management to allocate capital toward strategic priorities, including Medicare Advantage, value-based care initiatives, and healthcare technology investments.
The Evolution of Gentiva
From Kindred at Home to Gentiva
Humana’s connection to Gentiva began with its acquisition of Kindred at Home. After acquiring the organization, Humana identified several operations that did not align with its core insurance business.
In 2022, the company sold a 60% majority interest in Kindred at Home’s hospice and personal care divisions to private equity firm Clayton, Dubilier & Rice. These operations were then reorganized and rebranded as Gentiva.
Gentiva’s National Presence
Today, Gentiva stands as one of the largest providers of hospice and palliative care services in the United States. The organization operates more than 430 locations across 35 states and serves thousands of patients requiring end-of-life and supportive care services.
As a result, Gentiva remains a significant player in the hospice care market despite Humana’s departure from ownership.
Financial Details of the Transaction
The transaction values Humana’s remaining minority stake at approximately $900 million. While the company has not disclosed additional financial terms, it confirmed that a consortium of investors will acquire the stake.
Expected Use of Proceeds
Humana plans to use the proceeds for general corporate purposes. These funds may support strategic investments, strengthen the balance sheet, or provide additional financial flexibility as the company navigates changing healthcare market conditions.
Importantly, management stated that the transaction is not expected to have a material impact on earnings during 2026. Therefore, investors should view the sale primarily as a portfolio optimization initiative rather than a short-term earnings catalyst.
What the Deal Means for Humana
A Stronger Focus on Core Operations
By completing the sale, Humana officially closes the chapter on its ownership involvement in hospice and personal care businesses acquired through Kindred at Home. The move demonstrates a disciplined approach to capital allocation and strategic planning.
Moreover, the divestiture allows Humana to concentrate on areas where it has established competitive advantages. These include:
- Medicare Advantage plans
- Value-based care programs
- Primary care partnerships
- Healthcare technology and analytics
- Population health management
Positioning for Future Growth
Although hospice care remains an important healthcare service, Humana appears committed to focusing on insurance and care delivery models that support its long-term growth strategy. Consequently, the company can direct management attention and investment resources toward expanding member services and improving healthcare outcomes.
Industry Implications
The transaction highlights an ongoing trend across healthcare. Many insurers are reassessing ownership of provider assets and non-core healthcare services. At the same time, investors continue to show interest in hospice and palliative care organizations because of growing demand driven by an aging population.
Therefore, Gentiva’s future under a new investor group could create additional opportunities for expansion and innovation within the hospice sector.
Conclusion
Humana’s agreement to sell its remaining Gentiva stake for $900 million represents the final step in a strategic divestiture process that began several years ago. The deal simplifies the company’s portfolio, strengthens financial flexibility, and reinforces its focus on core healthcare operations.
As the transaction moves toward completion, both Humana and Gentiva appear positioned to pursue separate growth strategies. For Humana, the sale supports a sharper focus on insurance and value-based care. Meanwhile, Gentiva will continue operating as one of the nation’s largest hospice and palliative care providers under new ownership.
